(Q37975542)

26 August 2017

title

Aromatase inhibitors and breast cancer prevention (English)

1 reference

26 August 2017

4

Gabriel N Hortobagyi

1 reference

26 August 2017

author name string

Jennifer Keating Litton

series ordinal

1

1 reference

26 August 2017

Banu K Arun

series ordinal

2

1 reference

26 August 2017

Powel H Brown

series ordinal

3

1 reference

26 August 2017

language of work or name

English

0 references

publication date

14 January 2012

1 reference

Expert Opinion on Pharmacotherapy

26 August 2017

published in

1 reference

26 August 2017

volume

13

1 reference

26 August 2017

issue

3

1 reference

26 August 2017

page(s)

325-331

1 reference

Aromatase inhibitors for breast cancer: lessons from the laboratory

26 August 2017

cites work

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2012.651459

History of aromatase: saga of an important biological mediator and therapeutic target

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2012.651459

Endocrine therapy plus zoledronic acid in premenopausal breast cancer.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2012.651459

Safety of fertility preservation by ovarian stimulation with letrozole and gonadotropins in patients with breast cancer: a prospective controlled study

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2012.651459

Aromatization inhibition alone or in combination with GnRH agonists for the treatment of premenopausal breast cancer patients.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2012.651459

Effect of anastrozole and tamoxifen as adjuvant treatment for early-stage breast cancer: 100-month analysis of the ATAC trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2012.651459

Quality of life of postmenopausal women in the ATAC ("Arimidex", tamoxifen, alone or in combination) trial after completion of 5 years' adjuvant treatment for early breast cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2012.651459

Survival and safety of exemestane versus tamoxifen after 2-3 years' tamoxifen treatment (Intergroup Exemestane Study): a randomised controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2012.651459

Letrozole therapy alone or in sequence with tamoxifen in women with breast cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2012.651459

A comparison of letrozole and tamoxifen in postmenopausal women with early breast cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2012.651459

Letrozole compared with tamoxifen for elderly patients with endocrine-responsive early breast cancer: the BIG 1-98 trial.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2012.651459

Late extended adjuvant treatment with letrozole improves outcome in women with early-stage breast cancer who complete 5 years of tamoxifen

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2012.651459

Skeletal effects of exemestane on bone-mineral density, bone biomarkers, and fracture incidence in postmenopausal women with early breast cancer participating in the Intergroup Exemestane Study (IES): a randomised controlled study.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2012.651459

Reversal of skeletal effects of endocrine treatments in the Intergroup Exemestane Study

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2012.651459

Tamoxifen in treatment of intraductal breast cancer: National Surgical Adjuvant Breast and Bowel Project B-24 randomised controlled trial.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2012.651459

Tamoxifen for prevention of breast cancer: report of the National Surgical Adjuvant Breast and Bowel Project P-1 Study

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2012.651459

Update of the National Surgical Adjuvant Breast and Bowel Project Study of Tamoxifen and Raloxifene (STAR) P-2 Trial: Preventing breast cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2012.651459

Benefit/risk assessment for breast cancer chemoprevention with raloxifene or tamoxifen for women age 50 years or older

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2012.651459

Patient decisions about breast cancer chemoprevention: a systematic review and meta-analysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2012.651459

Exemestane for breast-cancer prevention in postmenopausal women

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2012.651459

10.1517/14656566.2012.651459

21 January 2018

Identifiers

DOI

1 reference

release_uwzw6re6jjfrblbsgx6gzvdvba

26 August 2017

Fatcat ID

1 reference

Fatcat

https://api.fatcat.wiki/v0/release/uwzw6re6jjfrblbsgx6gzvdvba

mapped directly with Wikidata item

24 November 2022

based on heuristic

1 reference